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| INTRODUC TI ON
Ischemia-reperfusion injury (IRI) is an inevitable consequence of renal transplantation and a major determinant of graft survival. Renal IRI is associated with deleterious consequences for several organs.
1,2
Accumulating clinical evidence has identified a close relationship between renal injury and injuries to other organ systems, including heart, lung, and liver. 3 Indeed, impaired liver function is often seen in patients with acute kidney injury (AKI). 4, 5 In addition, in-hospital death is more likely in patients with AKI and liver failure than in those with AKI alone. 6 The pathophysiology of remote liver injury after AKI is complex and incompletely understood, although both preclinical and clinical studies have shown that inflammation is an important mediator. 2 The exact functions of the various cytokines involved in regulating the complex inflammatory events after IRI are not yet fully unraveled.
7
The liver is particularly vulnerable to inflammatory challenge from the distant renal graft because it is abundantly perfused with systematic circulation. Liver injury could develop secondary to delayed graft function in a renal graft recipient. Remote hepatic injury is believed to be initiated and sustained by proinflammatory cytokines that are released or activated during IRI after renal damage. 8, 9 If liver repair and regenerative mechanism are not activated promptly, acute liver functional impairment could occur. Clinical management of such patients is difficult, and effective organ protective strategy is therefore required.
Recently, extracellular histone has been identified as a key inflammatory mediator in renal injury. 10 Histone is a highly conserved eukaryotic chromosomal protein. Under oxidative or inflammatory stress, histone undergoes translocation from the nucleus to the cytoplasm, and then it is secreted from the necrotic cells. 11 In the liver, histone has been shown to mediate hepatocyte cell death and inflammation. 12, 13 It is suggested that histone mediates cell death and inflammation by binding to Toll-like receptors (eg, TLR-4 and TLR-9).
14 Activation of TLRs may trigger the downward cascade including the inflammasome to activate pyroptosis and produce proinflammatory cytokines, exacerbating the injury and causing a systemic response. 15, 16 Pyroptosis is a lytic type of cell death and a form of regulated necrosis that is inherently associated with inflammation and distinguished from other forms of cell death by the associated secretion of interleukin (IL)-1β after caspase-1 activation. The cellular processes that occur during pyroptosis include nuclear condensation, DNA damage, cell swelling, and, finally, cell lysis, with the subsequent release of IL-1β and are reliant on intracellular sensors of bacterial products and formation of the inflammasome. Pyroptosis is a proinflammatory response that is triggered by a variety of pathologic stimuli, including myocardial infarction, stroke, and malignancy.
Various studies have indicated that pyroptosis is intrinsically involved in the development of infectious diseases, nervous system disorders, and atherosclerotic processes. [17] [18] [19] Pyroptosis is thought to be a key modulator of the immune response to microbial infection, while pathogens that have evolved and developed mechanisms to bypass pyroptosis demonstrate enhanced disease-causing and septic potential. 20 To date, there is a lack of studies about the effects of acute renal allograft injury on the liver. In the present study, we tested the hypothesis that IRI in renal allografts would initiate the distant hepatic injury. The underlying molecular mechanism, which is centered on pyroptosis, was also explored in this study.
| MATERIAL S AND ME THODS

| In vitro cell culture
Human hepatocyte HepG2 cells were cultured in EMEM, and human monocyte/macrophage U937 cells (European Cell Culture Collection, Porton Down, UK) were cultured in RPMI 1640 medium.
The culture medium was supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 2 mmol/L l-glutamine (Invitrogen), and 100 U/mL penicillin-streptomycin (Invitrogen). 
| Cell treatments in vitro
| Flow cytometry
Reactive oxygen species production was monitored by the measurement of superoxide (O ) generation by using the fluorescent dyes dihydroethidium (DHE). 22 Cells were incubated in DHE (2 μmol/L) for 30 minutes at 37°C in the dark. The cells were washed with PBS.
Fluorescence intensity was acquired and analyzed by using flow cytometry (FACSCalibur; Becton Dickinson, Sunnyvale, CA). Each assay included at least 10 000 gated events. Propidium iodide (PI;
Sigma Aldrich, St. Louis, MO) staining was used to examine cell death as described. Cells were harvested in a fluorescence-activated cell sorting (FACS) tube and washed twice before resuspension in FACS buffer. PI was added to make the final concentration to 1 μg/mL and incubated in dark for 5 minutes. PI fluorescence was detected by using flow cytometry. 
| Renal transplantation
| Animal treatment
All recipient animals received Cyclosporine A (5 mg/kg per day through intramuscular injection; Tocris, UK). The animals were administered histone H3 (calf thymus histone H3; Sigma-Aldrich) via intravenous injection (low dose 10 mg/kg, high dose 50 mg/kg). Livingston, UK) were administered to the rat recipients. 
| Hydrodynamic tail vein injection
| Hematoxylin-eosin staining
Liver samples obtained at various determination points were fixed in 4% buffered formalin and then embedded in paraffin, in accordance with standard procedures. Sections (5 μm) were stained with hematoxylin-eosin and examined microscopically. All samples were evaluated by an experienced pathologist who was blinded to the experiment. All fields in each section were examined for grading of steatosis and necroinflammation according to the Colantoni criteria. 25 
| TUNEL staining
Hepatic cell death was detected by using the in situ terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Millipore) according to the manufacturer's instructions. TUNELpositive nuclei were visualized by green FITC fluorescence.
| Immunohistochemistry
For in vivo fluorescence staining, the liver sample was fixed in 4% paraformaldehyde in 0.1 mol/L PBS solution overnight for 16 hours at 4°C.
This was followed by incubation in 30% sucrose solution for 24 hours at 
| Western blotting
Liver samples were mechanically homogenized in lysis buffer. The lysates were centrifuged, the supernatant was collected, and total 
| Enzyme-linked immunosorbent assay
Rat serum and liver tissue IL-1β, IL-18 (Rat IL-1β, IL-18 ELISA Kit;
Invitrogen, Paisley, UK), histone H3 (Histone H3 ELISA kit; LSBio), and VEGF (Rat VEGF Quantikine ELISA Kit; R&D, Abingdon, UK)
were measured with use of an ELISA. U937 medium IL-1β and interferon (IFN)-γ were assessed by ELISA (Human IL-1β and IFN-γ Elisa Kit; Invitrogen).
| Kidney and liver function
Blood samples were collected when animals were killed. After centrifugation, asparate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations were measured using AST and ALT Activity Assay Kit (Sigma Aldrich). Serum urea and creatinine concentrations were measured by using an Olympus AU2700 analyzer (Diamond Diagnostics, Watford, UK).
| Statistical analysis
All numerical data were expressed as mean ± SD. Data were analyzed with ANOVA followed by Kruskal-Wallis nonparametric (scoring) or Newman-Keuls (measurement) test for comparisons. A P value of <.05 was considered to be of statistical significance.
| RE SULTS
| IRI in renal graft caused remote liver injury after grafting
To 
| Enhanced inflammation was found in remote hepatic injury
Renal IRI was associated with a significant increase in CD68 
| Recombinant histone protein treatment exacerbates the remote hepatic injury
As indicated in Figure 5 , recombinant histone H3 protein treatment was found to exacerbate hepatic injury, with both low-dose and highdose histone administration associated with increased hepatic injury ( Figure 5A ) and increased liver injury score ( Figure 5D ) by almost 4-fold. High levels of hepatocyte steatosis and nuclear fragmenta- 
| VEGF-mediated cytoprotection in the remote liver injury
The capability for VEGF to attenuate pyroptosis in remote liver injury was assessed. In cultured hepatocytes treated with histone and in liver tissue with remote injury, expression of caspase-1 ( Figure 6A 
| Recombinant VEGF protein confers cytoprotection against histone-induced pyroptosis
Recombinant VEGF protein was found to confer cytoprotection against pyroptosis, as demonstrated in Figure 7G ). The expression of cleaved caspase-1 was also reduced by this treatment ( Figure 7K ). Recombinant VEGF also caused a significant improvement in hepatic function, as evidenced by a reduction in both ALT and AST levels in Figure 7L and M, respectively. These findings indicate that VEGF may be a potential therapeutic agent to attenuate pyroptosis in hepatic F I G U R E 3 Pyroptosis in remote hepatic injury in recipient with ischemic allografts. Renal graft from the Brown-Norway rat donor was stored in 4°C Soltran preservation solution for 24 h (cold ischemia rCI24 h), which was subsequently transplanted into Lewis rat recipients. Dual labeling of (A) caspase-1 (red) and ASC (green), (B) caspase-1 (red) and NLRP3, and (C) caspase-1 (red) and AIM2 (green). Nuclei were counterstained by DAPI. 
| Recombinant VEGF protein attenuates inflammation in remote hepatic injury
The administration of VEGF protein is found to be associated with 
| D ISCUSS I ON
In the present study, we demonstrated for the first time the progressive increase in histone release and induced pyroptosis during remote hepatic injury in a rat model of renal allograft transplantation. Blocking the histone-TLR-4 pathway prevented the hepatic pyroptosis caused by renal allograft IRI. In addition, VEGF was found to mitigate the histone-induced development of pyroptosis and subsequent hepatic inflammation and could serve as a therapeutic target within these pathophysiologic processes.
It is interesting to note that Nakazawa et al. recently investigated the role of circulating neutrophil extracellular traps and histones in remote organ injury after warm renal IRI. 26 The authors investigated the systemic effects of AKI on remote organs and found that tubular necrosis and neutrophil extracellular trap formation promote kidney injury and remote organ damage due to the systemic release of proinflammatory cytokines and histones. The onset of liver injury after IRI in renal allografts appeared in early stages of kidney injury and was associated with increased levels of proinflammatory cytokine and activated oxidative stress.
Histones are the proteins in chromatin that play an important role in controlling gene expression. 27 There are 2 kinds of histones: core histones (including H2A, H2B, H3, and H4) and linker histones (namely, H1 and H5). 27 Despite their vital role in gene regulation, histones in the extracellular space can cause inflammation and organ damage as reported in liver, lung, and kidney injury. 10, 12, 28 When necrosis takes place, the cell membrane ruptures and the cellular content, also known as damage-associated molecular patterns (DAMPs) including histones, would be released, causing inflammatory response.
29,30
The release of histones may also be associated with the formation of neutrophil extracelluar traps, which has shown to cause cell death in the lungs and endothelium. In the previous studies, an increased level of histone was toxic to liver and cause liver injury.
14 We have also demonstrated that naive animal and recipient animal, when receiving both low and high doses of histone, had significant liver damage, and blocking the its receptor TLR-4 through inhibitor reduced the injury; all these data indicated that the remote injury was effectively caused by extracellular histones. In addition, it is difficult to distinguish histone release from This warrants further investigation in future studies.
While it was initially believed that VEGF receptors were solely confined to the vascular endothelium, hence the name of the protein family, the presence of VEGF receptors has been acknowledged in a variety of cell types, including epithelial cells. 37 As a result, VEGF is capable of eliciting its effects on both epithelial and endothelial surfaces. VEGF-A binds with a high affinity to both VEGF-R1 and VEGF-R2, with VEGF-R2 undergoing more potent tyrosine phosphorylation after ligand activation, while VEGF-B solely interacts with VEGF-R1. 38 Although VEGF-R1 has shown a higher affinity to VEGF, approximately 10-fold higher than VEGF-R2, VEGF-R2 is considered a significant positive mitogenic signal transducer due to its strong kinase activity in comparison to VEGF-R1. 39 Various studies have demonstrated that VEGF-R2 upregulation promotes organoprotection. Activation of the VEGF-R2 pathway has been shown to mediate lung protection against oxidant-induced acute lung injury. and MyD88 pathways. 12, 15 The administration of neutralizing antibodies to extracellular histones (anti-H3 and anti-H4 antibodies) confers significant protection after hepatic IRI. 12 This is thought to occur due to the attenuation of tissue tumor necrosis factor-α and IL-6. Further investigation into the hepatoprotective effects of histone neutralization after hepatic IRI is warranted. Finally, human hepatocellular carcinoma cell line was used in in vitro study. It is very different in cell phenotype compared with primary hepatocytes, which are considered to be used for future study.
Patients with AKI often have liver dysfunction and may be associated with higher mortality. 4, 6 Although the effect of renohepatic crosstalk in renal graft recipients remains fully elucidated, our study indicates the role of circulating histones and their inflammatory effect on the liver. Extracellular histones, therefore, may be the target for therapy or prophylaxis against liver damage in kidney transplant patients.
In conclusion, our data suggest that a substantial release of histone in recipient after receiving ischemic renal allografts leads to 
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